Curve Biosciences

Biotech & Life Sciences · Mountain View, United States · Founded 2021

Unlocking the right data to help patients with chronic disease on their decades-long journey MoreLess

Curve Biosciences is a biotechnology company focused on precision medicine for chronic disease care. The company develops diagnostic and therapeutic products that target the biological changes occurring in tissues, which contribute to chronic diseases. Curve Biosciences aims to unlock the potential of Chronic Epigenetics to bring precision to chronic disease care.

Curve Biosciences is an early-stage company that is actively working on building its scientific team and advancing its research and development efforts. The company's business model likely revolves around the development and commercialization of its proprietary technologies and products. This could involve licensing agreements with larger pharmaceutical or biotech companies, as well as direct sales of its diagnostic and therapeutic solutions to healthcare providers and institutions.

Keywords: biotechnology, precision medicine, chronic disease care, diagnostics, therapeutics, epigenetics, healthcare, life sciences, medical research, biopharmaceuticals

Valuation $100–500M

Headcount <100

Total funding $50–100M

Unlock exact values

Company overview

Curve Biosciences company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2021
Headquarters: Mountain View, United States
Employees: 27
Open positions: 2
Dealroom signal: 78.1

Website ↗LinkedIn ↗

client focusb2bsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorMedical ResearchsectorResearch and DevelopmentsectorChronic DiseasesectorPrecision MedicinesectorSpinoutsectorBiotech and PharmasectorDT and LSsectorscience-based

Valuation & funding

Curve Biosciences funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Oct 2025	$40M	$160M	Incite · Civilization Ventures · First Spark Ventures · Mintaka	↗
EARLY VCOther financing	May 2024	$18M	$71M	Undisclosed	↗
SPINOUTOther financing	Jan 2021	$0	—	Stanford University	—

Showing 3 recorded eventsUnlock the complete deal history →

Growth signals

Curve Biosciences website traffic

Latest recorded traffic for Curve Biosciences is 100 monthly website visits, down 94.1% over the last three months. Curve Biosciences's team grew 0% over the past year.

Latest monthly visits100 3-month web change-94.1% 1-year team growth0%

Monthly website visits21 observations · May 2024–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Curve Biosciences compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational	15	$6M	$24M
PRProfionicsInnovative diagnostic solutions leveraging biomarkers and AI to rapidly detect and treat sepsis	Stevenage, United Kingdom	Operational
AMAmlogenyxAmlogenyx, a subsidiary of Ultragenyx Pharmaceutical, Inc., focuses on researching and developing new gene therapies for Alzheimer’s disease and other amyloid-related conditions	Somerville, United States	Operational
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired
NSNeuracle ScienceRetrocious nervous disorders, such as Alzheimer's disease, have become a major problem in modern society as well as the entry into the aging business	Seoul, South Korea	Operational
GBGennao BioGennao Bio is pioneering the development of targeted nucleic acid therapeutics using its unique, non-viral GMAB platform technology	Hopewell, United States	Operational
YBY BiologicsY-Biologics is Korea's leading R&D biotech company specializing in antibody drug development	Daejeon, South Korea	Operational
APAbarceo PharmaDeveloping small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D	Malmö kommun, Sweden	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Curve Biosciences's talent

Book a demo to see the people

Team profiled 6 named & role-tagged

Founders /100 quality score

Key operators 5 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

9 investors on Curve Biosciences's cap table

Sourced from Dealroom's funding and investor records.

Series A 8 investors entered at this stage

Luma Group

Incite

Civilization Ventures

First Spark Ventures

Mintaka

Micah S

Techas Capital

LifeX Ventures

Other known 1 additional known investor

Stanford University

Global footprint

Where Curve Biosciences has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

In the news

Latest news about Curve Biosciences

Recent press, funding announcements, and product moves mentioning Curve Biosciences — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Curve Biosciences

An AI-synthesized read of the highest-engagement posts about Curve Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Curve Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.